Lilly to acquire UK-based pharmaceutical company in deal worth up to $7.8B
Centessa Pharmaceuticals is developing treatments to address daytime sleepiness and other neurological conditions.
Eli Lilly and Co.
-
Eli Lilly begins using ‘mind-blowing’ LillyPod supercomputer at Indy campus
LillyPod, which occupies 30,000 square feet in a room the size of a football field, is capable of crunching massive amounts of data at high speeds and is expected to help the Lilly discover and develop drugs at a faster pace.
Read More -
Lilly, IU sign clinical trial, research agreement worth up to $40M
Officials say the pact, facilitated by the Indianapolis-based IU Launch Accelerator for Biosciences, is the largest single industry-sponsored agreement in the school’s history.
Read More -
Lilly, Nvidia team up to build pharma’s ‘most powerful’ supercomputer
The Indianapolis-based drugmaker said the supercomputer will power an “AI factory” designed to accelerate drug discovery and development.
Read More -
Q&A with the head of Lilly manufacturing, who meticulously tracks gains in work, life
“People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of management.”
Read More
Articles
Lilly asks U.S. Supreme Court to rule part of False Claims Act unconstitutional
The Indianapolis-based drugmaker is challenging a $183.7 million judgment in a case brought by a pharmacist who alleged Lilly made false claims about rebates to the federal Medicaid program.
Obesity drug trials complicated by placebo patients leaving early
The companies developing new weight-loss medicines have a problem: People who don’t lose weight quickly figure out they were assigned to take a placebo and are bailing out of their clinical trials.
Lilly’s experimental diabetes shot yields record weight loss in study
The late-stage results handily beat earlier trials of the company’s diabetes blockbuster Mounjaro, which racked up sales of $23 billion in 2025.
Lilly spending $1.8B to update Indianapolis manufacturing operations
The Lilly Technology Center investment includes expanding existing capabilities and the establishment of new production lines.
Lilly introduces direct-to-employer program for weight-loss drug
Eli Lilly and Co. has launched a platform that offers employers coverage options for obesity care through a partnership with 18 digital health programs.
Chief technology officer spent whole career at Lilly
Tim Coleman has held positions within information technology at Lilly in research and development, sales and marketing, manufacturing, and human resources.
CICP launches fund aimed at making Indiana a chemistry hub
The Catalyst Scholars Fund is supported by a $69.4 million grant from Lilly Endowment Inc. to the CICP Foundation Inc. and matching commitments from participating universities.
GLP-1 fight plays out in statehouses, courthouses
While major drugmakers tussle for market supremacy, they are also taking on compound pharmacies that have not stopped selling obesity drugs despite the end of the shortage of such drugs.
Lilly to acquire Massachusetts-based cell therapy firm for $2.4B
Orna is developing a treatment known as CAR-T cell therapy, a form of immunotherapy that trains a person’s own cells to recognize and destroy diseases.
Novo Nordisk vows to sue after Hims & Hers launches Wegovy knockoff pill
Shares in Indianapolis-based Eli Lilly and Co., a rival to Novo Nordisk in the weight-loss market, also fell after the announcement, dropping 7.8% Thursday.
Trump administration to launch TrumpRx website for discounted drugs
The president first teased TrumpRx in September while announcing the first of his more than 15 deals with pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., to lower drug prices.
Lilly earnings continue upward path on growth of Zepbound, Mounjaro
Eli Lilly and Co. shares soared in midday trading Wednesday after the drugmaker reported fourth-quarter results that topped Wall Street expectations.
Trump draws attention to Lilly’s massive building spree. Here’s what’s in the works.
Eli Lilly and Co. has announced $50 billion in U.S. expansion commitments since 2020, including numerous manufacturing plants all over the country.
Lilly to build $3.5B plant in Pennsylvania in 4th of 4 big U.S. investments
The new facility, part of a $27 billion reshoring investment, will produce the drugmaker’s weight-loss therapies.
Lilly signs $1.12B deal with Germany-based firm to develop hearing loss treatments
The agreement with Seamless is the latest in a series of purchases and partnerships Lilly has established to build a pipeline of genetic medicines.
Lilly receives FDA’s breakthrough therapy designation for ovarian cancer drug
Ovarian cancer is the fifth-leading cause of cancer death among women in the United States.
Popular weight-loss drugs shouldn’t carry suicide warnings, FDA says
U.S. Food and Drug Administration officials say a comprehensive review “found no increased risk” related to suicide among users of the GLP-1 drugs, including Eli Lilly and Co.’s Zepbound, used to treat obesity.
Lilly, Nvidia to establish $1B AI co-innovation lab in San Francisco
The new initiative expands on the massive artificial intelligence supercomputer collaboration the companies announced last fall.
Former GLP-1 users regain lost weight after about 18 months, study says
People who stop taking GLP-1 drugs such as Ozempic, Wegovy and Zepbound for weight loss are projected to regain their shed pounds within about 1-½ years, a review of existing research has found.